July 7, 2020 / 8:29 PM / a month ago

BRIEF-Nextcure Initiates Phase 1/2 Clinical Study Of NC410, A Novel Immunomedicine, For Solid Tumors

July 7 (Reuters) - NextCure Inc:

* NEXTCURE INITIATES PHASE 1/2 CLINICAL STUDY OF NC410, A NOVEL IMMUNOMEDICINE, FOR SOLID TUMORS

* NEXTCURE INC - ANTICIPATES INITIAL DATA FROM PHASE 1 PORTION OF TRIAL BY SECOND HALF OF 2021 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below